Hyrimoz
AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences
The new site will expand research capabilities across immunology, neuroscience and oncology
AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo
The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA
Sandoz announces collaboration agreement with Shanghai Henlius Biotech
The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma
Allergan Aesthetics launches Skin Quality Index for aesthetic consultations
Spanning four dimensions of skin health, the framework introduces 15 terms and definitions
Sandoz partners with Samsung Bioepis to develop up to five biosimilars
The agreement will expand the pipeline and builds on an existing partnership
Sandoz appoints Armin Metzger as President of new global unit
Metzger was most recently Executive VP, Chief Technical Operations Officer at Ferring Pharmaceuticals
AbbVie reaches agreement for affordable prescription drugs with US government
The pharma company has also pledged a $100bn investment in US infrastructure over the next decade
Sandoz launches first and only multiple sclerosis biosimilar in US
The treatment is FDA-approved to treat MS and Crohn’s disease
Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities
Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity
AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial
Follicular lymphoma affects around 15,000 people in the US every year